ARDX News & Events

Reports Q1 revenue $94.47M, consensus $92.61M. "In the first quarter of 2026, Ardelyx continued our strong commercial execution which coupled with our strengthening cash position allows us to conduct multiple IBSRELA clinical trials, advance development of our next-generation NHE3 inhibitor, RDX10531, and purposefully explore various avenues to build a significant and sustainable pipeline of important medicines," said Mike Raab, President and Chief Executive Officer of Ardelyx. "IBSRELA is the cornerstone for the company we're building and is on the path to becoming a blockbuster by achieving at least one billion dollars in revenue in 2029 with continued strong growth thereafter. We are in a position of financial strength, providing flexibility to allocate capital across the business, accelerate commercial momentum, and drive intrinsic long-term value for the Company, our patients, and our shareholders."

Jade Biosciences (JBIO) announced the appointment of Edward Conner as chief medical officer, effective immediately. Conner joins Jade from Ardelyx (ARDX) where he served as CMO.

Ardelyx announced the appointment of Felecia Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer, CLO. She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company.

Ardelyx (ARDX) announced the appointment of Rajani Dinavahi as chief medical officer. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. Dinavahi most recently served as senior VP, chief medical officer at Atara Biotherapeutics (ATRA).